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Introduction {#sec1}
============

Obesity is one of the most widespread problems facing our society's health today. Excessive weight significantly increases risk for conditions like diabetes mellitus and cardiovascular disease ([@bib12], [@bib40]). Worldwide, the prevalence of obesity has nearly tripled since 1975, with 39% of the world's adults being overweight and 13% being obese ([@bib41]). The high prevalence can partially be attributed to increasing consumption of hypercaloric foods and sedentary lifestyles ([@bib41]). Previous studies have identified metabolic signatures associated with obesity, including increased levels of branched-chain and aromatic amino acids as well as glycerol and glycerophosphocholines ([@bib4], [@bib6], [@bib13], [@bib24], [@bib29], [@bib31]). However, prior work has been limited by focusing on a relatively small numbers of metabolites, individuals, or obesity phenotypes.

The characterization of the metabolites that are associated with obesity can provide insights into the mechanisms that lead to this disease and associated consequences. Longitudinal assessment of weight gain and weight loss over time may indicate whether there are metabolomic changes that cause obesity---meaning that current metabolite levels could predict future weight changes---or whether all metabolite changes associated with obesity are a consequence of weight changes. Drawing genetics into this assessment allows the determination of whether genetic variation leads to metabolite changes that subsequently result in obesity, allowing the further delineation of the causal pathway to obesity. Finally, research in this area may identify biomarkers of obesity and of different types of obesity, for example biomarkers of so-called healthy obesity ([@bib26]).

There are recent calls to improve phenotyping in very large numbers of obese people with the goals of understanding factors that make people susceptible to (or protected from) obesity, accompanied by a better elucidation of the factors that account for variability in success of different obesity treatments ([@bib44]). Here, in an effort to understand the relationship between metabolic perturbations and the obese state, we analyzed 2,396 individuals with longitudinal measurements of body mass index (BMI), anthropomorphic data, whole-body DEXA scans, and metabolome, combined with baseline genetic risk. The metabolome assay covered up to 1,007 metabolites at up to three distinct time points for each individual over the course of study. We identified associations between nearly a third of the metabolome and BMI, and we show that metabolite levels can predict obesity status with ∼80%--90% specificity and sensitivity. The metabolome profile is a strong indicator of metabolic health compared to the polygenic risk assessment and anthropomorphic measurements of BMI.

Results {#sec2}
=======

Profound Perturbation of Metabolome by Obesity {#sec2.1}
----------------------------------------------

### Metabolites Associated with BMI {#sec2.1.1}

We compared the levels of individual metabolites to the BMIs of 832, 882, and 861 unrelated individuals of European ancestry in the TwinsUK cohort ([@bib25]) at three time points spanning a total range of 8--18 years. We identified 284 metabolites that were significantly associated (p \< 5.5 × 10^−5^) with BMI at one or more time points ([Table S1](#mmc2){ref-type="supplementary-material"}). We focused on 110 metabolites that were significantly associated with BMI at all 3 time points and sought to replicate the associations in an independent sample of 427 unrelated individuals of European ancestry participating in the Health Nucleus cohort ([@bib30]). In total, our analyses identified 307 metabolites that were significantly associated with BMI in at least one cohort and time point ([Table S1](#mmc2){ref-type="supplementary-material"}). We identified 83 metabolites that showed directions of effect that were consistent between the two cohorts, of which 49 were statistically significant replications ([Figure 1](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). While this set of 49 metabolites was the most stringently associated with BMI, the majority of the implicated metabolites (292 of 307, 95%) had directions of effect that were consistent between time points/cohorts, indicating that many of the remaining metabolites may reach our stringent cutoffs in a larger study.Figure 1Pathway Categories of Metabolites Associated with BMI(A and B) Shown are the pathway categories of (A) the 307 metabolites significantly associated with BMI and (B) the 49-metabolite signature.(C) The values of each of the 49 BMI-associated metabolites are plotted with a Loess curve against the BMI for time point 1 in TwinsUK. Only unrelated individuals of European ancestry are included, and the small number of individuals with BMI below 20 (n = 31) or above 40 (n = 10) are removed to keep the ends of the graphs from being skewed. The apparent inversion of the relationship between one cofactor/vitamin metabolite and BMI at higher BMIs is an artifact that is corrected once morbidly obese individuals are included.Table 1Metabolite Signature Associated with BMISuper PathwayMetaboliteSubpathway (Correlated Blood Lipids[c](#tblfn3){ref-type="table-fn"})Direction of Effect (Rank[a](#tblfn1){ref-type="table-fn"})BMI r^2^[b](#tblfn2){ref-type="table-fn"}NucleotideuratePur.Met.↑ (1)16.4%N2,N2-dimethylguanosinePur.Met.↑ (6)8.8%N6-carbamoylthreonyladenosinePur.Met.↑ (28)7.3%Amino acidglutamateGlu.Met.↑ (2)11.5%N-acetylglycineGly.Met.↓ (9)9.0%5-methylthioadenosine (MTA)Poly.Met.↑ (10)7.5%valineLeu.Met.↑ (11)8.8%aspartateAla.Met.↑ (16)7.0%N-acetylvalineLeu.Met.↑ (18)7.3%kynurenateTry.Met.↑ (19)6.0%alanineAla.Met.↑ (23)5.3%asparagineAla.Met.↓ (26)3.7%N-acetylalanineAla.Met.↑ (31)6.6%tyrosinePhe.Met.↑ (34)1.8%leucineLeu.Met.↑ (37)6.8%N-acetyltyrosinePhe.Met.↑ (40)4.2%2-methylbutyrylcarnitine (C5)Leu.Met.↑ (41)8.3%Lipid1-(1-enyl-palmitoyl)-2-oleoyl-GPCPlas. (HDL, TG)↓ (3)7.1%1-stearoyl-2-dihomo-linolenoyl-GPCPhos.Met. (TG, Chol)↑ (4)9.8%1-eicosenoyl-GPCLysolipid↓ (5)6.2%1-arachidoyl-GPCLysolipid↓ (7)8.6%1-(1-enyl-stearoyl)-2-oleoyl-GPCPhos.lip. (HDL)↓ (8)6.5%propionylcarnitineBCAA.Met↑ (12)9.9%1-nonadecanoyl-GPCLysolipid↓ (14)4.2%1-linoleoyl-GPCLysolipid↓ (15)4.9%sphingomyelinSph.Met. (Chol)↑ (20)6.8%1-palmitoyl-2-dihomo-linolenoyl-GPCPhos.Met. (TG, Chol)↑ (21)5.1%1-(1-enyl-palmitoyl)-2-linoleoyl-GPCPhos.Met. (HDL)↓ (22)5.7%1-palmitoyl-3-linoleoyl-glycerolPhos.Met. (TG)↑ (24)7.6%1-oleoyl-2-linoleoyl-GPCPhos.Met.↓ (27)5.6%1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPCPhos.Met.↓ (29)2.5%1-oleoyl-3-linoleoyl-glycerolDi.gly. (TG, HDL)↑ (30)6.3%carnitineCar.Met.↑ (33)7.5%1-palmitoyl-2-linoleoyl-glycerolPhos.Met. (TG, HDL)↑ (36)7.2%1-oleoyl-2-linoleoyl-glycerolDi.gly. (TG, HDL)↑ (38)5.9%1,2-dilinoleoyl-GPCPhos.Met.↓ (39)4.2%1-palmitoleoyl-2-oleoyl-glycerolPhos.lip. (TG)↑ (42)5.6%1-palmitoleoyl-3-oleoyl-glycerolPhos.lip. (TG)↑ (45)6.0%1-palmitoyl-2-adrenoyl-GPCPhos.Met. (TG)↑ (47)2.9%cortisonePlas. (HDL, TG)↓ (49)2.5%EnergysuccinylcarnitineTCA↑ (13)9.8%CarbohydratemannoseFru.Met.↑ (17)6.6%glucosePyr.Met.↑ (48)6.3%XenobioticscinnamoylglycineFood↓ (43)3.5%Cofactors/ vitaminsgulonic acidAsc.Met.↑ (46)3.2%quinolinateNic.Met.↑ (44)8.4%PeptideN-acetylcarnosineDipep.↑ (25)6.9%gamma-glutamylphenylalanineGam.↑ (32)6.0%gamma-glutamyltyrosineGam.↑ (35)4.6%[^2][^3][^4][^5]

The 49 metabolites that associated with BMI were primarily lipids (n = 23, accounting for 7.5% of all lipids assayed across both cohorts) and amino acids (n = 14, 9.3% of all amino acids) but also included nucleotides (n = 3, 12.0% of all nucleotides), peptides (n = 3, 12% of all peptides), and other categories (n = 6; [Figure 1](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). The most significantly associated metabolite was urate (uric acid; p value 1.2 × 10^−40^ for combined analysis of TwinsUK time point 1 and Health Nucleus data).

### Patterns in Metabolite Change According to BMI {#sec2.1.2}

The majority of the 49 BMI-associated metabolites increased with increasing BMI (n = 35) ([Figure 1](#fig1){ref-type="fig"}; [Table S1](#mmc2){ref-type="supplementary-material"}). This included glucose and, notably, mannose, which has recently been highlighted as playing a role in insulin resistance ([@bib19]). Most metabolites change linearly (both proportionally and inversely) with BMI ([Figure 1](#fig1){ref-type="fig"}C). Branched-chain and aromatic amino acids as well as metabolites related to nucleotide metabolism like urate had the most rapid increases. Those that decreased (n = 14) included phospholipids and lysolipids, as well as the amino acids asparagine and N-acetylglycine and the xenobiotic cinnamoylglycine, which has been identified as a product of the microbiome ([@bib42]). The negatively associated lipids tended to reflect HDL (high-density lipoprotein) levels, while the positively correlated lipids were more representative of triglyceride levels ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}). Of particular interest was the association between BMI and cortisone, a metabolite of the steroid hormone cortisol. We identified lower levels among the obese individuals, which is consistent with previous reports ([@bib2], [@bib32], [@bib39], [@bib43]). We examined the overall composition of the distributions of these metabolites via principal component analysis and found complex underlying correlations; in particular, the first principal component explained ∼20% of the total variation in the levels of these 49 metabolites. We additionally examined each of the 49 metabolites in just those of normal weight, overweight, or obese separately, and we found directions of effect that were largely consistent with those seen in the group as a whole ([Table S1](#mmc2){ref-type="supplementary-material"}).

### Modeling the Metabolome of Obesity {#sec2.1.3}

We used ridge regression to build a model that would predict BMI from the 49 BMI-associated metabolites ([Figure 2](#fig2){ref-type="fig"}). We chose this method to focus on the most stringently associated metabolites and to remove effects of collinearity, and we found similar results when using lasso regression. We combined our data for the first visit of the TwinsUK cohort and the Health Nucleus cohort and trained with 10-fold cross-validation on a random half of the population. In our test set of the other half of the data, we found that the model could explain 39.1% of the variation in BMI ([Figure 2](#fig2){ref-type="fig"}A). In predicting whether participants were obese (BMI ≥ 30) or normal weight (BMI 18.5--25), the model had an area under the curve (AUC) of 0.922, specificity of 89.1%, and sensitivity of 80.2% ([Figure S1](#mmc1){ref-type="supplementary-material"}). The model based on the metabolite signature was thereafter used as a tool to define mBMI, the predicted BMI on the basis of metabolome.Figure 2Variables Associated with BMI and Predicted BMI from the Metabolome(A) Correlation between ridge regression model prediction of BMI and actual BMI for all unrelated individuals of European ancestry in the TwinsUK and Health Nucleus dataset. The identification of outliers is defined below: the pink box shows individuals with a much lower predicted BMI (mBMI) than actual BMI, and the yellow box shows individuals with a much higher mBMI than actual BMI.(B) Factors associated with being an mBMI outlier. Participants were split into five groups: those whose metabolome accurately predicted their BMI (residual after accounting for age, sex, and BMI between −0.5 and 0.5) whose BMIs were either normal (18.5--25), overweight (25--30), or obese (\>30), and those whose metabolome predicted a substantially higher mBMI than the actual BMI (residual \< −0.5) or a substantially lower mBMI than the actual BMI (residual \> 0.5). All y axis values are scaled to a range from 0 to 1 to allow comparison across groups.(C) The same process is used to show DEXA imaging values associated with metabolic BMI outliers. The mBMI ≫ BMI and mBMI ≪ BMI groups had a comparable measured BMI and age; however, these two groups were statistically significantly different from each other (p \< 0.01) for all modalities except blood pressure, LDL, total cholesterol, and polygenic risk score. Additionally, the mBMI ≫ BMI group was statistically significantly different from normal weight, metabolically healthy people (p \< 0.01) for all traits (except LDL), while mBMI ≪ BMI individuals were only statistically different in diastolic blood pressure (p = 0.005). In contrast, outliers with mBMI ≪ BMI were always statistically significantly different from obese, metabolically obese individuals (except systolic blood pressure, LDL, and total cholesterol), while mBMI ≫ BMI individuals were only statistically different in percent body fat (p = 4.4 × 10^−6^). LDL, low-density lipoprotein; HDL, high-density lipoprotein. The correlations of each modality with mBMI can be found in [Table S2](#mmc3){ref-type="supplementary-material"}.Whiskers of boxplot extend to the most extreme points no greater than 1.5 times the interquartile range (distance between the first and third quartiles).

Richer models using the full set of available metabolites (n = 650 measured in both cohorts) improved the accuracy of the model (47%--49% of the variance explained) and could be considered as the optimal approach by accepting the additional cost of a full untargeted metabolome as compared to the more targeted panel of 49 metabolites. This performance should be contrasted with the results of models using routine clinical laboratory determinations: regression analysis predicting BMI from age, sex, HDL, LDL, total cholesterol, and total triglycerides explained 31% of the variation in BMI, whereas a model using age, sex, and the 49-metabolite signature explained 43% of the variation. In fact, even though mBMI was modeled by training on BMI, this metabolite signature had a better correlation than BMI with most health-related phenotypes measured here ([Table S2](#mmc3){ref-type="supplementary-material"}).

Identification and Characterization of Metabolic BMI Outliers {#sec2.2}
-------------------------------------------------------------

Having established a model to predict BMI using the metabolome (mBMI), we split the participants into five groups ([Figure 2](#fig2){ref-type="fig"}A). Three groups included individuals whose metabolome accurately predicted their BMI, as defined by having a residual between −0.5 and 0.5 from a regression analysis of mBMI with age, sex, and BMI included as predictors. These criteria delineated ∼80% of individuals as having an mBMI relatively concordant with actual BMI. They were characterized as having a normal BMI (18.5--25), overweight (25--30), or obese (\>30). Two groups were characterized as outliers: these included individuals whose metabolome predicted a substantially lower mBMI than the actual BMI (mBMI ≪ BMI, residual \< −0.5) or a substantially higher mBMI than the actual BMI (mBMI ≫ BMI, residual \> 0.5). While these two outlier groups had the same weight and age distribution ([Figure 2](#fig2){ref-type="fig"}B), they had very different values for many of the phenotypes of metabolic health collected from these cohorts ([Figures 2](#fig2){ref-type="fig"}B and 2C). Individuals with an mBMI prediction that was substantially lower than their actual BMI had levels of insulin resistance, total triglycerides, HDL, blood pressure, waist/hip ratio, android/gynoid ratio, percent body fat, percent visceral fat, and percent subcutaneous fat that were similar to normal-weight individuals with healthy metabolomes. Individuals with an mBMI prediction that was substantially higher than their actual BMI had levels for these traits that were similar to those of obese individuals with obese metabolomes. Evaluating these data from a more clinical perspective, with individuals separated into clinical categories such as normal BMI with obese metabolome and obese BMI with healthy metabolome, generally confirmed these effects ([Figures 3](#fig3){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). Our findings suggest that the metabolome can be used as a clinically meaningful instrument, where obesity is analyzed in the context of its metabolome perturbation rather than just on BMI alone. Thus, our results are important in the frame of the current debate on the metabolically "healthy" obese and also for the identification of individuals with normal BMI ([@bib6]) but poor metabolic health ([@bib5], [@bib14]).Figure 3Body Composition Profiles from Dixon Magnetic Resonance Imaging for Four Outlier Individuals(A) Correlation between ridge regression model prediction of BMI and actual BMI for all unrelated individuals of European ancestry in the TwinsUK and Heath Nucleus dataset. Outliers highlighted in (B) and (C) are marked with corresponding colors. All individuals highlighted are from the outlier mBMI ≫ BMI or mBMI ≪ BMI categories shown in [Figure 2](#fig2){ref-type="fig"}.(B) Body composition profiles (red, visceral adipose tissue; yellow, subcutaneous adipose tissue; cyan, muscle).(C) Waist to hip cross-sections (hip, mid femoral head; waist, top of ASIS).

Having characterized these outliers, we revisited their metabolome differences. As the 49 metabolites were chosen for their association with BMI, there is no *a priori* expectation that they would all show differences between the group with mBMI ≫ BMI and the group with mBMI ≪ BMI, as these two groups have the same BMI distribution. However, we found that these two outlier groups did indeed have statistically significant differences in their metabolite levels for all of the 49 metabolites but two: asparagine and cortisone ([Figure S3](#mmc1){ref-type="supplementary-material"}). This lack of association of cortisone with mBMI/BMI outliers shows that its correlation with BMI does not appear to extend to metabolic health, which presents interesting questions about the underlying biology. Although cortisone's parent compound cortisol has been reported as associated with obesity, there are inconsistent relationships between cortisol and metabolic parameters in the literature ([@bib1], [@bib15]). It is also known that cortisol levels change throughout the day, and this factor could have influenced our results as the participants were not all measured at the same time. We additionally investigated the association between each of the BMI-associated metabolites and insulin resistance, as many previously reported markers of obesity have also been markers of diabetes ([@bib13], [@bib29]). We had quantitative insulin resistance measurements for 515 unrelated, European-ancestry participants. After controlling for BMI, we found that 12 of the 49 BMI-associated metabolites were also significantly associated (correcting for 49 tests requires p \< 0.001) with insulin resistance, all with positive directions of effect: tyrosine, alanine, kynurenate, gamma-glutamyltyrosine, 1-oleoyl-3-linoleoyl-glycerol (18:1/18:2), six phospholipids, and, as expected, glucose ([Table S1](#mmc2){ref-type="supplementary-material"}). Mannose, which recently underwent extensive study with regard to insulin resistance ([@bib19]), was nominally associated with insulin resistance after controlling for BMI in our study (p = 0.004).

### Evolution of Obesity and Metabolome Clinical Profiles {#sec2.2.1}

Given recent work suggesting that obese individuals who are metabolically healthy may remain at higher risk of negative health outcomes than are normal weight individuals who are metabolically healthy ([@bib5]), we next asked whether the outlier groups were more likely to become obese over time. Focusing on the 1,458 individuals from TwinsUK who had weight measurements at all three time points, we found that those who had an mBMI that was higher than their BMI were marginally more likely to gain weight and convert to an obese phenotype (BMI \> 30) over the 8--18 years of follow up. For example, 32.8% of those of normal weight but with an overweight or obese metabolome converted to being overweight or obese by time point 3 compared to 24.8% of those who were of normal weight and had a healthy metabolome (p = 0.01; [Figure 4](#fig4){ref-type="fig"}). However, this association was not strongly supported, and overall, the mBMI states of the individuals remained fairly stable with time and were a function of BMI changes ([Figure 4](#fig4){ref-type="fig"}). For example, 68% of the individuals who began the study with an obese metabolome ended the study with an obese metabolome. When an individuals' weight increased and then decreased, their mBMI followed suit, and no single metabolite was significantly predictive of subsequent BMI changes. In summary, our results are consistent with a favorable long-term health benefit for the overweight and obese individuals with a healthy metabolome.Figure 4Progression of Different mBMI/BMI Categories(A) Alluvial plot showing the proportion of participants who remained in the same weight category or transitioned to a different weight category over the course of the 8--18 years of the TwinsUK study. Red individuals have an obese metabolome, orange individuals have an overweight metabolome, and gray individuals have a normal metabolome.(B) Alluvial plot showing the proportion of participants who remained in the same mBMI category or transitioned to a different mBMI category over the course of the 8--18 years of the TwinsUK study. Red individuals begin the study with an obese BMI, orange overweight, and gray normal weight.(C) Bar graph showing baseline rates of stroke, infarction, angina, angioplasty, any of the above, and blood pressure medication use at baseline for TwinsUK (with colors indicating groups as in D; n = 1,573 for information on cardiovascular and stroke events and 379 for information on blood pressure medication). Those with mBMI ≪ BMI had none of these conditions at baseline except stroke, while those with mBMI ≫ BMI had rates similar to those of overweight and obese individuals.(D) Survival plot showing age until cardiac event (infarction, angina, or angioplasty). The plot is divided into those whose mBMI corresponds with their BMI (normal weight (n = 598), overweight (n = 461), and obese (n = 192) categories) as well as the two outlier groups: those with mBMI ≪ BMI (n = 158) and those with mBMI ≫ BMI (n = 164) (p = 0.003 for a difference between these categories in cardiovascular outcomes).

### Cardiovascular Disease Outcomes {#sec2.2.2}

Obesity is considered a risk factor for cardiovascular disease and ischemic stroke ([@bib34]). In the TwinsUK study, 32 of 1,573 individuals reported having had a cardiovascular event (myocardial infarct, angina, or angioplasty) or stroke prior to baseline. We found significant differences between mBMI/BMI groups in their reported baseline cardiovascular events (Fisher's exact p = 0.01). In particular, the mBMI ≪ BMI outliers had no history of cardiovascular events, whereas the mBMI ≫ BMI outliers had a proportion of historical events that was similar to those of overweight and obese individuals ([Figure 4](#fig4){ref-type="fig"}C). Information about blood pressure medication use was also available for 379 individuals at baseline, and those with mBMI ≫ BMI had very high rates of use compared to mBMI ≪ BMI (Fisher's exact p = 0.00003; [Figure 4](#fig4){ref-type="fig"}C). The longitudinal nature of the TwinsUK study also allowed the collection of clinical endpoints in these unselected participants. The age of participants at the first visit ranged from 33 to 74 years old (median 51), and 42 to 88 years old (median 65) at the last visit. During the follow up (median 13 years), the study recorded 53 cardiovascular events (myocardial infarct, angina, or angioplasty) or strokes for 1,573 individuals. We calculated that our study had 80% power to identify effects with a hazard ratio of at least 1.5 for differences in cardiovascular event outcomes between the different mBMI/BMI groups. We found that participants with a healthy metabolome (normal BMI, overweight, or obese) had 2.6 events per hundred individuals. Individuals with an obese metabolic profile, mBMI, had 3.4 (normal/overweight BMI) and 4.4 events (in obese individuals) per hundred individuals. Separated analysis of the various endpoints confirmed the trends, more accentuated for cardiovascular than for diagnosis of stroke. We then performed a formal survival analysis for participants to have any cardiovascular event after the first time point, and we found those with healthier metabolomes to have fewer/later cardiac events (p = 0.003; [Figure 4](#fig4){ref-type="fig"}D).

### Correlations between Twins {#sec2.2.3}

Because twin studies are important to analyze the heritability of traits, we reassessed the BMI model predictions and obesity status of 350 sets of twins where either both twins had normal BMI (n = 244), both twins were obese (n = 67), or one was obese and the other had normal BMI (n = 39). To keep the categories clear, individuals with BMIs between 25 and 30 (overweight) and their twins were excluded. As asserted by the model's high specificity and sensitivity, the metabolite-based obesity predictions reflected the actual obesity status of the individuals. This was even the case when only one twin was obese: the obese twin was generally predicted by their metabolome to be obese, while the normal weight twin was not ([Figure S1](#mmc1){ref-type="supplementary-material"}). The correlations between the metabolite-based obesity predictions were also substantially higher between the monozygotic twins than the dizygotic twins, as expected. Interestingly, we identified three sets of twins where both twins were predicted from the metabolome to be of normal weight, but both were obese, and eight sets of twins where the reverse was true. These outliers were thought to represent healthy obese and normal weight, metabolically unhealthy individuals described above.

Genetic Analyses {#sec2.3}
----------------

### Known Genetics of Obesity {#sec2.3.1}

We first investigated the known genetic factors contributing to high BMI. We calculated polygenic risk scores for BMI using known associations from the considerable literature of obesity and BMI GWAS (genome-wide association study) ([@bib21]). As previously reported, we found that polygenic risk score only explained 1.2%--2.2% of the variation in BMI at each of the three TwinsUK time points and in Health Nucleus for unrelated participants of European ancestry ([Figure S4](#mmc1){ref-type="supplementary-material"}). We investigated whether unique individuals with the highest polygenic risk scores would have a significant perturbation of the metabolome and anthropomorphic, insulin resistance, and DEXA measurements ([Figure 5](#fig5){ref-type="fig"}). While the data did not support a strong role for polygenic risk, there were trends for higher polygenic risk scores to be associated with a higher android/gynoid ratio (p = 0.04), waist/hip ratio (p = 0.03), and triglycerides (p = 0.01). However, there was no statistical association between the polygenic score and mBMI (p = 0.07).Figure 5Genetic Risk Compared to BMI-Relevant Variables(A) Correlation between polygenic risk score (PG) category, *MC4R* carrier status, and BMI and anthropomorphic and clinical measurements for all unrelated individuals of European ancestry in the TwinsUK and HN dataset. All y axis values are scaled to a range from 0 to 1 to allow comparison across groups.(B) The same process is used to show blood work and DEXA imaging values. While there was a trend for genetic risk to be associated with various measurements, the polygenic risk score achieved nominal p \< 0.05 for BMI, waist/hip ratio, android/gynoid ratio, and triglycerides, and *MC4R* carrier status achieved nominal p \< 0.05 for BMI. LDL, low-density lipoprotein; HDL, high-density lipoprotein.Whiskers of boxplot extend to the most extreme points no greater than 1.5 times the interquartile range (distance between the first and third quartiles).

Studies of rare variants in obesity have identified melanocortin 4 receptor (*MC4R*) mutations as having effects large and clear enough to be appropriate for study in our dataset ([@bib9], [@bib37]). We therefore identified members of the study populations who were carrying rare (MAF \< 0.01%) coding variants in *MC4R*. We identified eight such carriers in the subset of unrelated participants ([Table 2](#tbl2){ref-type="table"}). Each variant was observed in one unrelated individual, and six of the eight had already been annotated as causing obesity in clinical databases HGMD or ClinVar ([Table 2](#tbl2){ref-type="table"}). As a group, *MC4R* carriers had significantly higher BMI (p = 0.02) than did non-carriers as well as non-significant trends toward a higher diastolic blood pressure, insulin resistance, and percent body fat ([Figure 5](#fig5){ref-type="fig"}). However, it is known that not all rare variants are deleterious, and the metabolic impact could have been greater for the true subset of functional variants. The BMI data in the participants supported a pathogenic role for at least five of the variants (Met292fs, Arg236Cys, Ser180Pro, Ala175T, and Thr11Ala), but did not corroborate a role of Ile170V, which is defined in HGMD, ClinVar, and the literature as pathogenic ([@bib7], [@bib9], [@bib18], [@bib35]). Importantly, of the five sets of twins who both carried the same *MC4R* variant, three sets included twins who were both overweight or obese. In the two cases where a carrier's twin did not have the *MC4R* variant, their BMI was lower than their twin's. We observed an enrichment of *MC4R* variant carriers among obese individuals with low polygenic risk scores ([Figure S4](#mmc1){ref-type="supplementary-material"}). Out of 37 participants who were obese with polygenic risk scores in the lowest quartile, 5.4% were *MC4R* variant carriers, while the carrier frequency was just 0.4% in those of normal weight.Table 2Variants Identified in *MC4R* or Lipodystrophy Genes in Participants of European AncestryGeneVariantProtein ChangeStudy MAFGlobal Gnomad MAFKnown Functional AnnotationCarrier BMI (mBMI)Carrier Twin BMI (mBMI)Non-carrier Twin BMI (mBMI)Twin Zygo-sity**Obesity***MC4R*chr18:60371541 G/Ap.Ser270Phe0.04%0.00%none25.7 (26.1)24.8 (24.7)N/AMZ*MC4R*chr18:60372307 G/Ap.Leu15Phe0.04%0.00%none23 (22.6)22.6 (22.4)N/AMZ*MC4R*chr18:60371474 CA/Cp.Met292fs0.04%\<0.003%(complete LOF)[b](#tblfn5){ref-type="table-fn"}32.8 (26)N/A28.8 (24.3)DZ*MC4R*chr18:60371644 G/Ap.Arg236Cys0.04%0.00%HGMD highC DM (not LOF)[b](#tblfn5){ref-type="table-fn"}34.5 (32.3)30 (27.5)N/ADZ*MC4R*chr18:60372319 T/Cp.Thr11Ala0.04%\<0.003%HGMD lowC DM (not LOF)[b](#tblfn5){ref-type="table-fn"}36 (31.7)N/AN/AN/A*MC4R*chr18:60371812 A/Gp.Ser180Pro0.04%\<0.003%ClinVar LP (partial LOF)[b](#tblfn5){ref-type="table-fn"}34.2 (30.2)34.4 (33.5)N/ADZ*MC4R*chr18:60371827 C/Tp.Ala175Thr0.04%0.02%ClinVar P HGMD highC DM (partial LOF)[b](#tblfn5){ref-type="table-fn"}29 (25.6)28.5 (24.4)N/AMZ*MC4R*chr18:60371842 T/Cp.Ile170Val0.04%0.01%ClinVar P HGMD highC DM (partial LOF)[b](#tblfn5){ref-type="table-fn"}22.6 (23.7)N/A21.3 (24.7)DZ**Lipodystrophy***ZMPSTE24*chr1:40290870 G/GTp.Leu362fs0.11%0.03%ClinVar P18 (18.9)N/AN/AN/A*ZMPSTE24*chr1:40290870 G/GTp.Leu362fs0.11%0.03%ClinVar P22 (20.3)N/AN/AN/A*ZMPSTE24*chr1:40290870 G/GTp.Leu362fs0.11%0.03%ClinVar P22.4 (26.1)N/A22.6 (25.1)DZ*ZMPSTE24*chr1:40290870 GT/Gp.Leu362fs0.04%\<0.003%not annotated[a](#tblfn4){ref-type="table-fn"}30.7 (27.5)N/A24.9 (24.1)DZ*AGPAT2*chr9:136673876 G/Cp.Ala238Gly0.04%0.00%HGMD highC DM20 (23.3)N/AN/AN/A*LIPE*chr19:42401821 CCCCCCGCAGCCC CCGTCTA/Cp.Val1068fs0.04%0.07%ClinVar P23 (27.4)N/AN/AN/A*BSCL2*chr11:62692371 C/Tc.863+5G\>A0.04%\<0.003%ClinVar P24 (29.9)N/AN/AN/A[^6][^7][^8]

We also searched the study population for rare variants associated with Mendelian lipodystrophy syndromes. Lipodystrophies are heterogeneous, genetic, or acquired disorders characterized by selective loss of body fat and associated metabolic complications such as diabetes mellitus, hypertriglyceridemia, and hepatic steatosis ([@bib11]). We identified six individuals with rare heterozygous variants in four genes: *ZMPSTE24*, *AGPAT2*, *LIPE*, and *BSCL2* ([Table 2](#tbl2){ref-type="table"}). The individuals with *LIPE* or *BSCL2* variants were of normal weight but were in the mBMI ≫ BMI outlier category. The three individuals with *ZMPSTE24* p.Leu362fs caused by a 1-bp insertion had normal to low BMI and mBMI. We also observed an unannotated 1-bp deletion at this site in one obese individual ([Table 2](#tbl2){ref-type="table"}; [Figure S5](#mmc1){ref-type="supplementary-material"}). While these observations are interesting, there are no data in the literature to support a phenotypic role for these variants in carriers (heterozygotes).

### Genetics of the Metabolically Healthy Obese {#sec2.3.2}

Individuals with an mBMI that was substantially lower than their actual BMI had a higher polygenic risk score for BMI than did other groups. In contrast, those whose mBMI was substantially higher than their actual BMI had low polygenic risk scores ([Figure 2](#fig2){ref-type="fig"}B; p = 0.08 for a difference between these two groups). This result would support the notion that the polygenic risk score for BMI may capture an anthropomorphic phenotype (larger-framed individuals) rather than a unique association with obesity as a disease trait.

### Genetics of Metabolome Differences {#sec2.3.3}

Last, we investigated whether obese individuals with different genetic backgrounds had different metabolomes from other obese individuals. We first searched for metabolites, BMI-associated or otherwise, that could distinguish individuals with different BMI polygenic risk scores or *MC4R* variant carriers. Linear regression showed no significant associations between any single metabolites and polygenic risk or *MC4R* carrier status in either the entire population or in only the obese individuals. This result implies that metabolites are unlikely to be intermediate phenotypes that explain the underlying genetics of obesity. To check for more specific signals beyond the compiled polygenic risk score, we also performed separate analyses of each of the 97 variants that are used to calculate the polygenic risk score. We found no evidence for any of these known GWAS variants to be more strongly associated with a metabolite than with BMI itself, though our power for discovery was limited given the very small effect sizes of most individual GWAS variants. In summary, although it is known that there is a strong genetic component to metabolite levels ([@bib22]), most of the metabolic perturbations that occur in the obese state are a response to obesity as opposed to shared genetic mechanisms.

Discussion {#sec3}
==========

The results of the present study highlight the profound disruption of the metabolome in obesity and identify a metabolome signature that serves to examine metabolic health without the limitations of anthropomorphic measurements or the cost, time, and equipment requirements of imaging technologies. Nearly one-third of the approximately 1,000 metabolites measured in the study were associated with BMI, and 49 were selected as a strong signature for the study of the relationship between BMI, obesity, metabolic disease, and the genetics of BMI.

Consistent with previous studies and earlier work in the TwinsUK cohort, branched-chain and aromatic amino acids, and metabolites involved in nucleotide metabolism, such as urate and pseudouridine, are strongly perturbed by obesity ([@bib4], [@bib13], [@bib24], [@bib29]). The underlying reason for the perturbation of branched-chain amino acid metabolism in obese individuals and those with insulin resistance is thought to be related to differences in the amino acid catabolism in adipose tissue ([@bib27]). The single metabolite with the most significant association with BMI was urate, as we previously reported ([@bib24]). It is well known that uric acid increases with obesity, due to insulin resistance reducing the kidneys' ability to eliminate uric acid, but previous work has not emphasized the power of urate to predict BMI ([@bib4], [@bib10], [@bib13]). We also found a strong signal for lipids to be associated with BMI, with an enrichment of associations found for glycerol lipids. These results are consistent with previous studies showing that sphingomyelins and diacylglycerols increase with BMI while lysophosphocholines decrease with BMI, with other various phosphatidylcholines having effects in both directions ([@bib4], [@bib13], [@bib29]). A number of BMI-associated metabolites (12 of the 49-metabolite signature) were associated with insulin resistance after controlling for BMI. As previously observed ([@bib5], [@bib28], [@bib33], [@bib38]), the metabolome abnormalities associated with high BMI corrected with loss of weight. However, our study found that metabolite levels did not provide predictive power for future weight changes. Overall, the metabolome perturbations appear as a consequence of changes in weight as opposed to being a contributing factor.

While BMI correlates well and to a large extent with individual health outcomes, it does not have the sensitivity to identify outliers, some of which carry unique health consequences. These limitations to BMI are recognized in the literature ([@bib26]). Here, the metabolome signature identified individuals whose predicted mBMI was either substantially lower or higher than their actual BMI, i.e., individuals with lesser or greater metabolic consequences of obesity, using a technology that is amenable to large-scale implementation. These individuals include the metabolically healthy obese, but we also emphasize the importance of the metabolome anomalies in identifying unhealthy individuals with a normal BMI. These profiles were generally stable over the prolonged follow up. An abnormal metabolome was associated in the present study with an approximately 5-fold increase in baseline cardiovascular events and additional 2-fold increase in cardiovascular events during follow up when comparing individuals who were matched for BMI but who had opposing metabolome signatures. Thus, while our findings are in line with the known relationships between metabolically healthy obese status and health-related traits like metabolic syndrome and body fat ([@bib3], [@bib5], [@bib16]), we extend this relationship to the broader category of metabolically healthy and unhealthy individuals on the basis of the disparity between mBMI and BMI. For example, we observed differences in waist/hip ratio, percent visceral fat, and blood pressure between mBMI/BMI outliers despite having the same BMI distribution. The fact that the metabolically healthy obese have a high BMI polygenic risk score also supports the concept that some of the genetic studies may capture anthropomorphic associations---body size---rather than obesity *sensu stricto*. Overall, the health consequences observed across the various mBMI groups indicate that there is a durable benefit of maintaining a healthy metabolome signature and point to an ongoing risk for the individuals that have an unhealthy metabolome despite stability of BMI.

In line with the observation that a richer set of biomarkers is more accurate than a narrower panel of single biomarkers, we observed that 650 metabolites could explain \~50% and a 49-metabolite signature of the best markers could explain 43% of variance in BMI. In contrast, a conventional model that included age, sex, HDL, LDL, total cholesterol, and triglycerides could explain 31%, while the best single metabolic marker (urate) could explain 16% of the variance in BMI. The message that emerges from these types of observations---and that will become central to the implementation of machine and deep learning in medicine---is that there is a substantial loss of signal associated with the quest for a single biomarker. The medical system would, however, need to validate and establish the health economics of rich data biomarkers to foster adoption in clinical diagnostic routine.

In contrast with metabolomics analyses, the present study does not support a strong association between metabolome changes and the genetics of BMI defined by a 97-variant polygenic risk score ([@bib21]). This may be explained by the fact that known BMI GWAS loci explain only a small fraction (∼3%) of BMI heritability ([@bib21]). Despite this overall lack of explanatory power, there was a clear signal for individuals with higher polygenic risk scores to have greater rates of obesity. Because the genetic risk score does not include rare variants, we also identified individuals who carried rare functional variants in the known obesity gene *MC4R*, which is the single best example of a gene where rare coding variants have a large effect on obesity ([@bib37]). The carriers of these variants were often obese individuals, but their metabolome was not categorically different from that of other obese individuals. The lack of metabolome differences for carriers of variants in this gene is not surprising given that *MC4R* variants cause obesity by increasing appetite. However, we did find that obese carriers of *MC4R* variants often had low polygenic risk scores for obesity; out of 31 participants who were obese with polygenic risk scores in the lowest quartile, 5.4% were *MC4R* variant carriers, while the carrier frequency was just 0.4% in those of normal weight. Thus, our study shows the interest of sequencing obese individuals with low polygenic risk scores because of the apparent enrichment for monogenic contributions. As we completed this study, a large consortium provided additional detail on the role of variants in pathways that implicate energy intake and expenditure in obesity ([@bib37]). Future studies should also explore the role of rare functional variants in lipodystrophy genes on the metabolic traits in the general population.

In summary, the present study highlights the health risks of the perturbed metabolome. The study also indicates that the genetics of BMI are separate from metabolic health and serves to prioritize a subset of individuals for genetic analysis. The assessment of the metabolome and genome of BMI lays groundwork for future studies of the heterogeneity of obesity and treatment of its endophenotypes. Specifically, the methodology used here can be applied to build similar models for insulin resistance, fat distribution, or any other number of clinical traits, and the mBMI metabolome signature can act as a biomarker of response to the new therapeutics that target patients with *MC4R* mutations ([@bib17]). In the future, metabolic profiling could help select patients for clinical trials beyond genetic sequencing, thus expanding drug utility ([@bib44]).

Limitations of Study {#sec3.1}
--------------------

While the uniquely rich metabolomic and phenotypic data in this study permitted a thorough investigation of obesity-related health, there were nonetheless limitations. We chose to focus this study on BMI, the most widely used measurement of obesity. However, future studies building models for other traits of metabolic health, for example diabetes or visceral fat, may be of greater utility. Our study also had limited longitudinal information on medication use, which precluded an analysis of how drug prescription influenced mBMI/BMI categories and vice versa. Additionally, the association we observed between mBMI/BMI categories and longitudinal cardiovascular outcomes requires confirmation in a replication cohort.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Deposited Data**gnomad, Genome Aggregation Database<http://gnomad.broadinstitute.org/>RRID: SCR_014964ClinVar<https://www.ncbi.nlm.nih.gov/clinvar/>RRID: SCR_006169HGMD, Human Gene Mutation Database<http://www.hgmd.cf.ac.uk/ac/index.php>RRID: SCR_001888Study data deposited into Mendeley DataThis paper; <https://data.mendeley.com/><https://doi.org/10.17632/kpjsnwd2mc.1>Study data and scripts deposited into GitHubThis paper; <https://github.com><https://github.com/humanlongevity/mbmi>**Software and Algorithms**R Project for Statistical Computing<http://www.r-project.org/>RRID: SCR_001905FaST LMM<https://github.com/MicrosoftGenomics/FaST-LMM>RRID: SCR_015506

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Elizabeth Cirulli (<liz.cirulli@gmail.com>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

The study included 1,969 largely European ancestry twins enrolled in the TwinsUK registry, a British national register of adult twins ([@bib25]). We previously reported a detailed study of the genetic variants influencing the human metabolome in this cohort ([@bib22]). Serum samples were collected at three visits, 8-18 (median 13) years apart. The cohort is mainly composed of females (96.7%), and the sample set we used included 388 monozygotic twin pairs, 519 dizygotic twin pairs, and 155 unrelated individuals. The age of participants at the first time point ranged from 33 to 74 years old (median 51); 36 to 81 years old (median 59) at the second time point; and 42 to 88 years old (median 65) at the third time point. The BMI values measured at each metabolome time point were taken within two years of the blood draw date. At baseline, 36.3% of the female participants and 53.8% of the male participants were overweight, and 16.9% of the females and 10.8% of the males were obese. The twins study was approved by St. Thomas' Hospital Research Ethics Committee, and all participants provided informed written consent. BMI data were available for 1743 participants within two years of the time point for metabolome time point 1, 1834 for within two years of time point 2, and 1777 for up to 2 years before time point 3 or 4 years after this time point; 1,458 individuals had all three datapoints.

For independent validation and studies of phenotypes correlated with metabolic BMI outliers, we enrolled 427 unselected adults more than 18 years old who were able to come to the Health Nucleus in La Jolla, CA for a clinical research protocol ([@bib30]). Participants underwent a verbal review of the institutional review board-approved consent (Western Institutional Review Board). Participants ranged in age from 18-89 years old (median 53), were 32.9% female, and had BMI data measured at one time point: 16.7% of the female participants and 47.5% of the male participants were overweight, and 7.2% of the females and 23.7% of the males were obese.

Method Details {#sec4.4}
--------------

### Phenotyping {#sec4.4.1}

Individuals in the TwinsUK cohort and Health Nucleus both underwent dual-energy X-ray absorptiometry (DEXA) imaging. The data from these scans were used to calculate android/gynoid ratio, percent body fat, visceral fat, and subcutaneous fat. DEXA is very accurate in the measurement abdominal visceral adipose tissue (VAT). High levels of VAT are associated with atherogenic dyslipidemia, hyperinsulinemia, and glucose intolerance ([@bib26]). TwinsUK cohort participants were additionally measured for circumference at the waist and hip using a measuring tip to calculate the waist/hip ratio. TwinsUK participants self-reported information about whether they were taking high blood pressure medication at their first visit and about cardiovascular events and their timing via a survey at the final visit. For a selected number of Health Nucleus participants, images of fat and water (imaging of muscle) were available from symmetrical chemical shift Magnetic Resonance Imaging (MRI) via the Dixon method. Quantitative insulin resistance (homeostatic model assessment, HOMA) was calculated as fasting insulin x fasting glucose / 405, and being insulin resistant was defined by HOMA score ≥ 3 (<http://gihep.com/calculators/other/homa/>) ([@bib23]).

### Metabolite Profiling {#sec4.4.2}

The non-targeted metabolomics analysis of 901 metabolites in the TwinsUK cohort and 1,007 metabolites in the Health Nucleus cohort was performed at Metabolon (Durham, North Carolina, USA) on a platform consisting of four independent ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. The detailed descriptions of the platform can be found in our previous publications ([@bib8], [@bib22]). For the TwinsUK cohort, blood serum after fasting was used for analysis, and the resulting raw values were transformed to z scores using the mean and standard deviation. For the Health Nucleus cohort, blood plasma after fasting was used for analysis, and values from multiple experimental batches were normalized into Z-scores based on a reference cohort of either 42 (n = 457) or 300 (n = 176) self-reported healthy individuals run with each batch. The 42 and 300-normalized batches were converted to the same scale using linear transformation based on the values obtained from 7 runs that included both the 42 and 300 controls. Samples with metabolite measurements that were below the detection threshold were imputed as the minimum value for that metabolite.

### Genome Sequencing and Analysis {#sec4.4.3}

As previously described ([@bib36]), DNA samples were sequenced on an Illumina HiSeqX sequencer utilizing a 150 base paired-end single index read format. Reads were mapped to the human reference sequence build HG38. Variants were called using ISIS Analysis Software (v. 2.5.26.13; Illumina). A linear mixed model was applied to account for family structure in the cohort while testing for associations between genetic variants and the different phenotypes: BMI; BMI prediction model values and residuals after accounting for BMI, age, sex; and levels of the 49 BMI-associated metabolites. A genetic similarity matrix (GSM) was constructed from 301,556 variants that represented a random 20% of all common (MAF \> 5%) variants genome-wide after linkage-disequilibrium (LD) pruning (r^2^ less than 0.6, window size 200 kb) and was used to model the random effect in the linear mixed model via a "leave-out-one-chromosome" method for each tested variant. Each of 97 known BMI-associated variants was tested independently using customized Python scripts wrapping the FaST-LMM package (FaST LMM, RRID: [SCR_015506](rridsoftware:SCR_015506){#intref0065}) ([@bib20], [@bib21]). Principal component axes were calculated to check ethnicity using plink, and the first principal component for those of European ancestry was used as a covariate in analyses of unrelated individuals in R described below. Polygenic risk scores were calculated using genotypes for 97 variants whose associations and betas had been published previously ([@bib21]). Rare variants in the gene *MC4R* were defined as coding and splice variants with MAF \< 0.1%. Rare lipodystrophy variants were defined as those achieving a pathogenic or likely pathogenic categorization in ClinVar (ClinVar, RRID: SCR_006169) or HGMD (HGMD, RRID: [SCR_001888](rridsoftware:SCR_001888){#intref0070}). Allele frequencies were calculated in our set of samples and also retrieved from gnomad (Genome Aggregation Database, RRID: SCR_014964).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

R (R Project for Statistical Computing, RRID: SCR_001905) was used for the analysis and data manipulation. Bonferroni correction was used for all analyses, and most statistical analyses were restricted to unrelated individuals of European ancestry, in accordance with field standards for ensuring that ancestry differences do not cause bias or skew in the results. For each quantitative analysis of BMI or other traits, the subset of BMI values or other outcome variables used were rank-ordered and forced to a normal distribution. Analyses comparing metabolites to BMI were performed in R using the lm function, and age, sex, and the first genetic principal component were included as covariates. The obesity prediction model was built using ridge regression (alpha = 0) with glmnet in R. The residuals used to separate participants into the five categories shown in [Figure 2](#fig2){ref-type="fig"} were calculated using age, sex, and initial BMI. Heatmaps were generated in R using the pheatmap package. Survival analysis was performed using coxph in R with age at first visit included as a covariate. Power calculation was performed using the power.stratify command in the powerSurvEpi package in R.

Data and Software Availability {#sec4.6}
------------------------------

The R analysis scripts and data files used are available at <https://github.com/humanlongevity/mbmi>. Data files have been deposited to Mendeley Data and are available at <https://doi.org/10.17632/kpjsnwd2mc.1>.
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[^1]: Lead Contact

[^2]: Subpathway acronyms: Ala.Met., alanine and aspartate metabolism; Asc.Met., ascorbate and aldarate metabolism; BCAA.Met, branched-chain amino acid metabolism; Car.Met., carnitine metabolism; Di.gly., diacylglycerol; Dipep., dipeptide derivative; Food, food component/plant; Fru.Met., fructose, mannose, and galactose metabolism; Gam., gamma-glutamyl amino acid; Glu.Met., glutamate metabolism; Gly.Met., glycine, serine, and threonine metabolism; Leu.Met., leucine, isoleucine, and valine metabolism; Lysolipid, lysolipid; Nic.Met., nicotinate and nicotinamide metabolism; Phe.Met., phenylalanine and tyrosine metabolism; Phos.lip., phospholipid; Phos.Met., phospholipid metabolism; Plas., plasmalogen; Poly.Met., polyamine metabolism; Pur.Met., purine metabolism; Pyr.Met., glycolysis, gluconeogenesis, and pyruvate metabolism; Sph.Met., sphingolipid metabolism; Steroid, steroid; TCA, TCA cycle; Try.Met., tryptophan metabolism.

[^3]: Rank indicates order of significance of association with BMI.

[^4]: Mean r^2^ indicates the percent variation in BMI explained by each metabolite in univariate analysis for a combined analysis of the first time point of the TwinsUK cohort and the Health Nucleus data.

[^5]: Blood labs for TG (triglycerides), Chol (cholesterol), HDL (high-density lipoprotein), or LDL (low-density lipoprotein) that had an r^2^ \> 0.1 with the metabolite are indicated in parentheses.

[^6]: MAF, minor allele frequency; HGMD highC DM, Human Gene Mutation Database high-confidence disease-causing mutation; lowC, low confidence; ClinVar LP, likely pathogenic; P, pathogenic; MZ, monozygotic; DZ, dizygotic. Each variant was only seen once in the unrelated participants of this study. See alignments in [Figure S5](#mmc1){ref-type="supplementary-material"}.

[^7]: This deletion at the same site as a lipodystrophy insertion has not previously been annotated.

[^8]: Functional annotation according to [@bib9], where LOF = loss of function.
